Keywords: دیسکینزی; Parkinson's disease; Dyskinesia; Sleep disorder;
مقالات ISI دیسکینزی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دیسکینزی; cerebral palsy; dyskinesia; dystonia; hyperkinesia; hypertonia; spasticity;
Keywords: دیسکینزی; Parkinson's disease; Levodopa; Dyskinesia; Nicotine; Dopamine;
Keywords: دیسکینزی; Dyskinesia; Parkinson's disease; Levodopa; Nitric oxide; NOS1 gene; LID; Levodopa-induced dyskinesia; PD; Parkinson's disease; MDS-UPDRS; International Parkinson and Movement Disorders Society - Unified Parkinson's Disease Rating Scale; SNP; single nucleo
Keywords: دیسکینزی; Parkinson's disease; MPTP; marmoset; psychosis; dyskinesia; mianserin;
Keywords: دیسکینزی; Movement disorder-like features; Dyskinesia; Rating scales; Children; Age;
Keywords: دیسکینزی; Glycine receptor antibody; Status epilepticus; Autoimmune encephalitis; Paediatric; Dyskinesia;
Keywords: دیسکینزی; Parkinson's disease; Motor assessment; Spiral tests; Tapping tests; Smartphone; Dyskinesia; Bradykinesia; Objective measures; Telemedicine;
Keywords: دیسکینزی; 5-Alpha-Reductase; finasteride; l-DOPA; dyskinesia; Parkinson's disease;
Keywords: دیسکینزی; Antipsychotic; Deep brain stimulation; Dyskinesia; Psychosurgery; Subthalamic nucleus; Tardive dystonia;
Keywords: دیسکینزی; Parkinson's disease; Enteral infusion; Duodopa; Disability; Dyskinesia; AE; Adverse event; DDS; Dopamine dysregulation syndrome; ESS; Epworth Sleepiness Scale; HRQoL; Health-related Quality of Life; HYS; Hoehn-Yahr Stage; ICD; impulse control disorders; I
Keywords: دیسکینزی; Duloxetine; Dyskinesia; Norepinephrine transporter; OFF time; Serotonin transporter; Parkinson's disease;
Keywords: دیسکینزی; Seizure; Dog; Dyskinesia; Treatment; Progression
Keywords: دیسکینزی; Dyskinesia; Levodopa; Motor Fluctuations; Parkinson's Disease; AR; Akinesia/rigidity; CI; confidence interval; DA; dopaminergic agonists; DFS; dyskinesias-free survival; DK; dyskinesia; MC; motor complications; MF; motor fluctuation; MFFS; motor fluctuati
Keywords: دیسکینزی; Off-period dystonia; Dyskinesia; Parkinson's disease; Deep brain stimulation (DBS); L-DOPA, Direct (D1) and indirect (D2) pathway;
Keywords: دیسکینزی; Movement disorders; Deep brain stimulation; Parkinson's disease; Dyskinesia; Dystonia
Keywords: دیسکینزی; Inertial sensors; Support vector machine; Parkinson's disease; Dyskinesia; Ambulatory monitoring;
Keywords: دیسکینزی; Paroxysmal; Movement disorders; Dyskinesia; Episodic; Ataxia; Genetics;
Keywords: دیسکینزی; Angiogenesis; Dyskinesia; Ibuprofen; l-dopa; Parkinsonism; Piroxicam; Rat;
Keywords: دیسکینزی; Anosognosia; Self-awareness; Parkinson's disease; Dyskinesia; Neurodegenerative disorder; BDI-2; Beck-Depression-Inventory 2; DRT; dopamine replacement therapy; FDG; 18F-2fluoro-2-deoxy-d-glucose; FWE; family-wise error; IFG; inferior frontal gyrus; ISA;
Keywords: دیسکینزی; Parkinson's disease; Dyskinesia; Clinically important change; Minimally clinical important difference; Treatment; Clinical trial
Keywords: دیسکینزی; Parkinson's disease; Serotonin; Globus pallidus; Dyskinesia; Positron emission tomography;
Keywords: دیسکینزی; Parkinson's disease; 6-Hydroxydopamine; Dyskinesia; Basal ganglia; Preproenkephalin; Preprodynorphin;
Keywords: دیسکینزی; Dyskinesia; Dystonia; Myoclonus; Scales; Tics; Tremor;
Keywords: دیسکینزی; 5-HIAA; 5-hydroxyindolacetic acid; 5-HT; serotonin; 6-OHDA; 6-hydroxydopamine; AIMs; Abnormal involuntary movements; ARC; activity-regulated cytoskeletal-associated protein; DA; dopamine; DOPAC; 3,4-dihydroxyphenylacetic acid; EDTA; ethylenediaminetetraac
Keywords: دیسکینزی; Parkinson's disease; Levodopa; Dyskinesia; Hypokinesia; Dopamine agonists; Continuous dopaminergic stimulation;
Keywords: دیسکینزی; Psychosis; Schizophrenia; Dyskinesia; Movement abnormality; Conversion; Prodromal;
Keywords: دیسکینزی; Dyskinesia; Motor performance; Parkinson's disease; Repetitive transcranial magnetic stimulation; Supplementary motor area;
Keywords: دیسکینزی; Drug-induced movement disorders; Parkinsonism; Dyskinesia; Tremor; Acute dystonic reaction; Akathisia; Neuroleptic malignant syndrome; Serotonin syndrome
Keywords: دیسکینزی; Rotigotine; Parkinson's disease; Dyskinesia; Levodopa;
Keywords: دیسکینزی; Parkinson's disease; Dyskinesia; Levodopa; Motor cortex; Spine; Plasticity; Animal model; 6-Hydroxydopamine; Whole-cell patch clamp; Miniature excitatory postsynaptic currents;
Keywords: دیسکینزی; Parkinson's disease; MPTP; Non-human primate; Model; Dyskinesia
Keywords: دیسکینزی; Dyskinesia; Depression; Anxiety; Aggressiveness; Anorexia; Serotonin5,7-DHT, 5,7-hydroxytryptamine; 5-HIAA, 5-hydroxyindolacetic acid; 5-HT, serotonin; 8-OH-DPAT, 8-hydroxyy-2-(diproopylamino)tetralin hydrobromide; AADC, amino acid decarboxylase; ACTH, ad
Keywords: دیسکینزی; Parkinson's disease; Quality of life; Motor complications; Motor fluctuations; Dyskinesia; Europe;
Keywords: دیسکینزی; Spiral drawing; Dyskinesia; Tapping; Bradykinesia; Self-assessment; Telemedicine;
Keywords: دیسکینزی; Parkinson's disease; Dyskinesia; Plasticity; Transmagnetic stimulation; Inhibition;
Keywords: دیسکینزی; Aromatic l-amino acid decarboxylase deficiency; Mouse knock-in model; Neurotransmitter; Dopamine; Serotonin; Dyskinesia; Splicing;
Keywords: دیسکینزی; Parkinson's disease; Dyskinesia; Wearing off; Drug delivery; Rotigotine;
Keywords: دیسکینزی; Apomorphine; Parkinson's disease; Motor fluctuations; Dyskinesia; Visual hallucinations
Keywords: دیسکینزی; carbidopa; dopamine agonists; dyskinesia; levadopa; Parkinson's disease
Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model
Keywords: دیسکینزی; Dyskinesia; NR2B; Phosphorylation; Tat-Src;
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Keywords: دیسکینزی; L-DOPA; 5alpha-reductase; Dutasteride; Parkinson's disease; Dyskinesia; 6-OHDA; Neurosteroids; Dopamine;
Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease
Keywords: دیسکینزی; Parkinson's disease; Dyskinesia; DRD1-3 and BDNF genes; Haplotypes;
Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia
Keywords: دیسکینزی; Levodopa; l-dopa; Dopamine-induced dyskinesia; Dyskinesia; DRD; Dopa-responsive dystonia; Dopamine; Dopamine agonist; Carbidopa-levodopa; Ropinirole; Wearing off phenomenon; DYT5; Motor fluctuation; GCH-1;
The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset
Keywords: دیسکینزی; EMD-281,014; Parkinson's disease; Psychosis; Dyskinesia; Pharmacokinetics; Marmoset;
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements
Keywords: دیسکینزی; 6-OHDA; 6-hydroxydopamine; AIMs; abnormal involuntary movements; ALO; axial, forelimb and orolingual; ANOVA; analysis of variance; Arc; activity-regulated cytoskeleton-associated protein; CDS; continuous dopaminergic stimulation; COMT; catechol-O-methyltr
Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT1A receptor biased agonists
Keywords: دیسکینزی; Systems neurophysiology; Parkinson's disease; Dyskinesia; 6-OHDA rat; Oscillations; Local field potential;
Striatal norepinephrine efflux in l-DOPA-induced dyskinesia
Keywords: دیسکینزی; Parkinson's disease; l-DOPA; Dyskinesia; Norepinephrine; Striatum; Anti- DBH saporin;
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology
Keywords: دیسکینزی; L-DOPA; Dyskinesia; Parkinson's disease; Metabolomics; Striatum;
mGlu4 allosteric modulation for treating Parkinson's disease
Keywords: دیسکینزی; Parkinson's disease; Dyskinesia; Glutamate; Dopamine; mGlu4; 6-OHDA; 6-hydroxydopamine; ADX88178; 4-methyl-N-[5-methyl-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-yl]pyrimidin-2-amine; AIM; abnormal involuntary movements; CODA-RET; complemented donor acceptor reson